In the world of sustainable food innovation, The EVERY Company has firmly established itself as a trailblazer. Known for crafting highly functional protein ingredients, EVERY recently announced a significant milestone: a $2 million award from the U.S. Department of Defense (DoD) to explore domestic manufacturing capabilities. This funding, part of the Distributed Bioindustrial Manufacturing Program, marks a critical step in both the company’s growth and the U.S. government’s commitment to bolstering domestic biomanufacturing.
The grant will enable EVERY to assess the feasibility of establishing a U.S.-based manufacturing facility for its two flagship proteins. These include a highly soluble protein optimized for protein-boosting applications and ovalbumin, a revolutionary functional egg and egg white replacement. The latter recently earned a foundational patent, solidifying EVERY’s position as a leader in alternative protein technology.
Biomanufacturing for National Security and Beyond
The Distributed Bioindustrial Manufacturing Program underscores the vital role biomanufacturing plays in national security, spanning areas such as fabrication, firepower, fitness, food, and fuel. For the DoD, investing in biomanufacturing addresses critical supply chain vulnerabilities while advancing innovations in food technology. In the words of Arturo Elizondo, EVERY’s CEO, “Investing in biomanufacturing will allow the United States to safeguard reliable domestic supply chains, reduce reliance on foreign imports, and establish itself as a leader in food technology, especially in the face of rising global challenges such as food insecurity, zoonotic disease risk, and climate change.”
This strategic vision aligns seamlessly with EVERY’s mission. The company, which has primarily relied on production facilities in Europe and Asia, now has the opportunity to strengthen its domestic presence. Such an expansion not only enhances U.S. manufacturing capabilities but also supports local economies by utilizing homegrown feedstocks like U.S.-produced corn.
Revolutionary Applications and Military Use-Cases
As part of its partnership with the DoD, EVERY will develop military-specific applications for its proteins, particularly its soluble protein. This protein, celebrated for its versatility, has the potential to address critical nutrition challenges in compact and portable formats. Imagine a glass of water that delivers 20 grams of protein without altering its taste or appearance—a concept EVERY has already proven feasible.
EVERY’s production process, already demonstrated at an industrial scale exceeding 100,000 liters, offers remarkable efficiency compared to traditional protein sources. By using significantly less land and water and avoiding the environmental impact of animal agriculture, EVERY represents a sustainable path forward. The company has also achieved U.S. FDA approval for its entire portfolio, further solidifying its readiness for mass-market entry.
Scaling Production and Commercial Reach
Despite its groundbreaking technology, EVERY recognizes that scaling production remains a critical challenge. “Most of our customers require thousands of metric tons of product,” Elizondo shares. The $2 million DoD award will provide crucial support in expanding production capacity to meet growing demand. This focus on scaling comes at a pivotal moment for EVERY, as the company transitions from a niche innovator to a mass-market player.
EVERY has not only demonstrated its technical capabilities but also forged influential partnerships to accelerate its market penetration. Collaborations with industry leaders such as Grupo Nutresa, Grupo Palacios, and Unilever’s Vegetarian Butcher have positioned EVERY’s proteins in a wide array of consumer products, from plant-based Spanish omelets to vegan protein snacks.
Building on Past Achievements
This latest DoD funding builds on a series of achievements that have defined EVERY’s trajectory. Founded with the vision of reimagining protein production, the company has secured substantial backing from investors including McWin, a leading European food-tech fund, and Temasek, Singapore’s sovereign wealth fund. In recent years, EVERY has consistently outperformed expectations, proving the scalability and market viability of its precision fermentation process.
The company’s recent patent for ovalbumin—a milestone achievement—further reinforces its technological edge. This patent ensures that EVERY maintains exclusivity over the use of its egg protein alternative across a wide range of applications, from baked goods to functional beverages. It also paves the way for future innovation, as the company continues to explore new ways to harness its proteins for both consumer and industrial purposes.
Looking Ahead
The journey ahead is ambitious but promising. With its sights set on domestic production and an ever-expanding global footprint, The EVERY Company is well-positioned to redefine how the world thinks about protein. By combining cutting-edge technology, sustainable practices, and strategic partnerships, EVERY embodies the future of food in a way that is as functional as it is visionary.
For the United States, EVERY’s success represents more than just a technological advancement—it’s a step towards greater self-reliance, stronger supply chains, and a more sustainable future. For EVERY, this latest chapter is another affirmation of its potential to lead a global transformation in the way we produce and consume protein.
Comments